Terminal
Stocks
Spotlight
Research

Stocks
Healthcare
NASDAQ
IBRX

Market Cap: $8.28B

II

ImmunityBio, Inc.

IBRX

NASDAQ (NASDAQ Global Select)USD

Overview News Analyst Reports Financials Politician Trades Insider Trades Executive Patents Earnings Surprise

By Cashu Finance. Providing market news, analysis, and research for investors worldwide.

Company

Stocks About Advertisers Brokers Contact

Legal

Terms of Service Privacy Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Finance is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Finance is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Finance and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

ImmunityBio (IBRX) Financials & Key Data

Financials

Profitability

Gross Profit Margin94.63%

EBITDA Margin-5.36%

EBIT Margin-5.48%

Pre-tax Margin-5.99%

Net Profit Margin-5.99%

Earnings Yield-11.95%

Valuation Multiples

Price / Book-7.94

Price / Sales49.97

Price / Earnings-8.12

PEG0.07

Forward PEG0.10

EV / Sales54.42

Cash Flow & Capital

Free Cash Flow / Share-$0.35

Operating Cash Flow / Share-$0.34

Free Cash Flow Yield-4.41%

Capex / Revenue5.51%

Capex / Operating Cash Flow-2.56%

Capex / Depreciation0.44

Liquidity & Leverage

Current Ratio5.72

Quick Ratio5.70

Cash Ratio0.99

Debt / Assets1.29

Debt / Capital-3.48

Debt / Equity-0.78

Efficiency & Working Capital

Asset Turnover0.26

Fixed Asset Turnover1.14

Inventory Turnover4.59

Receivables Turnover3.10

Payables Turnover0.74

Days Sales Outstanding117.72

Returns & Quality

Return on Equity1.35%

Return on Assets-1.58%

Return on Invested Capital-45.01%

ROCE-45.63%

Return on Tangible Assets-1.61%

Operating Return on Assets-39.49%

Balance Sheet & Intrinsic Metrics

Enterprise Value$9.02B

Invested Capital$519.58M

Working Capital$362.25M

Tangible Asset Value$-1.06B

Net Current Asset Value$-1.24B

Graham Net-Net

Financial Health Scores

Piotroski Score3

Altman Z-Score-11.15

Revenue$165.79M

EBIT$-909.32M

Market Cap$8.09B

Working Capital$362.25M

EV / EBITDA

-10.16

EV / Operating Cash Flow-25.31

EV / Free Cash Flow-24.68

Price / Free Cash Flow-22.66

Price / Operating Cash Flow-23.30

Stock Compensation / Revenue25.62%

Dividend Payout Ratio0.00%

Dividend Yield0.00%

Long-Term Debt / Capital

-2.84

Debt / Market Cap9.35%

Net Debt / EBITDA-0.83

Solvency Ratio-0.58

Financial Leverage-0.60

Days Inventory Outstanding79.46

Days Payables Outstanding491.49

Operating Cycle197.19

Cash Conversion Cycle-294.3

Working Capital Turnover0.44

Income Quality0.22

Tax Burden1.00

Interest Burden1.09

-$1.21

Book Value / Share-$1

Tangible Book Value / Share-$1.01

Cash / Share$0.34

Retained Earnings

$-4.59B

Total Assets$628.5M

Total Liabilities$1.67B